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ABSTRACT 
Proteomic Characteristics of the Giant Congenital Melanocytic Nevi 
 
Yong Kyu Kim 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
(Directed by Professor Kwan Chul Tark) 
 
Background: Giant congenital melanocytic nevi (GCMN) are distress to 
patients and parents for two reasons. One is disfigurement and the other 
is possibility of malignant change. But development of GCMN and the 
underlying mechanism of melanotumorigenesis in GCMN are unknown.  
Objective: The aim of this study was to identify the proteomic 
alterations and associated functional pathways in GCMN.  
Methods: We harvested 6 GCMN skins and 6 normal skins which were 
harvested from 3 GCMN donor patient and 3 from normal patient who 
were treated in plastic surgery department. Mean age of patient is 8.9 
years. Group 1 samples include 3 GCMN and 3 normal skin samples(2 
matched skins and 1 normal skin) which were used for proteomic 
analysis with One dimensional liquid chromatography mass 
spectrometry(1D-LC MS/MS) analysis and Group 2 samples include 3 
GCMN and 3 normal skin samples( 2 normal skins and 1 matched skin) 
were used for western blotting analysis.  
The properties of the differentially expressed proteins (DEPs) were then 
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further analyzed using the bioinformatics tools STRING, PANTHER, and 
ClueGO.  
Results: Among the total proteins in GCMN, changes in the expression 
of 50 were found to be DEPs significantly (p < 0.05, student t-test) down 
(4 proteins) or upregulated (46 proteins). Among the DEPs with a 
molecular function, chaperone proteins (15.7% of total DEPs) were the 
most highly altered, whereas among the DEPs involved in biological 
processes, alterations were mostly seen in signal transduction proteins 
(15.3% of total DEPs). Specifically, neurotrophin signaling, melanosome, 
and downregulated of MTA-3 in ER-negative breast tumors proteins 
were maximally implicated. Moreover, increases in the expression of 
members of the 14-3-3 protein family appeared be associated with key 
cellular biological functions in GCMN. Among the five isoforms of the 
14-3-3 family (alpha, beta, zeta, epsilon, and tau), western blot analysis 
confirmed the upregulation of 14-3-3 epsilon in GCMN.  
Conclusion: We found the intensive alteration of 14-3-3 family proteins 
as a possible key regulator of GCMN biological pathway remodeling, 
which has important role in development of GCMN and could be 
associated with melanotumorigenesis.  
 
 
---------------------------------------------------------------------------------------- 
Key Words: congenital melanocytic nevi, melanotumorigenesis, 
melanoma, 14-3-3 epsilon.  
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I. Introduction 
    
Giant congenital melanocytic nevi (GCMN) are pigment cell 
malformations that are visible at birth, as well as nevi manifesting 
congenital features that become clinically apparent shortly after birth 1. In 
either case, they are likely the result of aberrant melanocyte migration, 
differentiation, and deposition in the dermis during the early stages of 
embryogenesis 2.  
   Although the absolute risk for developing melanoma in association 
with GCMN is low, GCMN is considered to be a risk factor in malignant 
melanoma 3, especially in individuals with larger malformations (over 20 
cm in diameter) 4. Several genomic and proteomic analysis have been 
performed to elucidate the mechanism of melanotumorigenesis from 
GCMN. Gene-based analyses revealed that oncogenic BRAF 5 and NRAS 
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6 mutations are frequently seen in GCMN. Also, broad Bcl-2 expression 
in GCMN has been suggested to suppress apoptosis, which otherwise 
plays an important role in the maintenance of nevocytes 7. In spite of 
these observations, the major biological processes and pathways of 
melanotumorigenesis remain unclear.  
   Proteomic profiling of certain diseases has been increasingly used to 
acquire data on a large number of proteins to identify potential 
biomarkers and to gain insight into the underlying mechanisms of a 
variety of diseases. However, the massive amount of generated 
information often only increases the complexity of these analyses. In 
response, a systemic approach to the proteomic data was developed. In 
this study, the systemic properties of GCMN were assessed, with the aim 
of gaining insight into the functional association between GCMN and 
melanotumorigenesis. Specifically, we used label-free liquid 
chromatography-mass spectrometry (LC-MS) proteomics and applied 
bioinformatics tools to identify proteins that may play a key role in the 
malignant transformation of GCMN. A total of 50 proteins (DEPs) found 
to be differentially expressed in normal skin and GCMN could be tightly 
organized in functional clusters. Importantly, several members of the 
14-3-3 family of proteins, thought to be regulators of oncogenesis, were 
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found to be upregulated. The results of this study might improve our 
understanding of the possible mechanisms that give rise to GCMN 
melanotumorigenesis. 
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II. Materials and Methods 
1. Patients 
  3 normal skin samples and 6 GCMN samples from GCMN patients 
were obtained and 3 normal skin samples were obtained from patients 
who underwent scar revision or skin graft procedures in the Department 
of Plastic Surgery, Inje University Ilsan Paik Hospital, Korea. The 
collection and use of the samples were approved by the institutional 
review board of Inje University Ilsan Paik Hospital.  
 
2. Sample preparation 
All skin samples were defatted surgically. Excised skin samples were 
categorized as 2 groups for analysis and validation, Group 1 include 3 
GCMN and 3 normal skin samples (2 matched skins and 1 normal skin) 
for proteomic analysis with 1D-LC MS/MS analysis. Group 2 include 3 
GCMN and 3 normal skin samples (1 matched skin and 2 normal skins)  
for  western blotting analysis.  
Group 1 samples were ground to a powder in liquid nitrogen, dissolved 
in lysis buffer (9 M urea, 2 M thiourea, 4% CHAPS 
(3-[(3-cholamidopropyl)dimethylammonio] -1-propanesulfonate), 40 
mM dithiothreitol, and 1% protease inhibitor cocktail), vortexed, and 
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incubated on ice for 1 h. The mixture was then centrifuged (10,000 × g, 
30 min, 4°C) and the total proteins contained in the supernatant used for 
the experiments. The total protein content of the solution was determined 
using the 2D Quant kit (GE Healthcare, Milwaukee, WI, USA), with 
serum BSA (0–50 mg/mL) as the standard. 
 
3. One-dimensional LC-ESI-MS/MS proteome analysis 
   Protein separation and LC-MS analysis were performed as previously 
described 8. Briefly, dissolved skin proteins were separated on a 12% 
polyacrylamide gel by SDS-PAGE. The gels were washed three times 
with ddH2O for 5 min each and then stained with Bio-Safe Coomassie 
stain solution (Coomassie G250 stain; Bio-Rad, Hercules, CA, USA) for 
1 h, with gentle shaking at room temperature. The 15 protein bands 
detected on the Coomassie-stained gels were evenly excised and then 
destained by incubation in 75 mM ammonium bicarbonate/40% ethanol 
(1:1). Disulfides were reduced by treatment with 5 mM DTT/25 mM 
ammonium bicarbonate at 60°C for 30 min, followed by alkylation with 
55 mM iodoacetoamide at room temperature for 30 min. The gel pieces 
were then dehydrated in 100% acetonitrile (ACN), dried, and swollen 
overnight at 37°C in 10 µl 25 mM ammonium bicarbonate buffer 
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containing 20 µg modified sequencing grade trypsin (Roche Applied 
Science, Indianapolis, IN, USA)/ml. The tryptic peptide mixture was 
eluted from the gel with 0.1% formic acid. LC-MS/MS analysis was 
performed using a ThermoFinnigan ProteomeX workstation LTQ linear 
ion trap MS (Thermo Electron, San Jose, CA, USA) equipped with NSI 
sources (Thermo Electron). Briefly, 12 μl of peptide sample from the 
in-gel digestion was injected and loaded onto a peptide trap cartridge 
(Agilent, Palo Alto, CA, USA). Trapped peptides were eluted onto a 
10cm reversed-phase (RP) PicoFrit column packed in-house with 5μm 
300-Å pore size C18, then separated by gradient elution. The mobile 
phases consisted of H2O and ACN, both containing 0.1% v/v formic acid. 
The flow rate was maintained at 200 nl/min. The gradient started at 2% 
ACN, then reached 60% ACN in 50 min, 80% ACN in the next 5 min, 
and 100% H2O in the final 15 min. Data-dependent acquisition (m/z 
400–1800) was enabled, and each MS survey scan was followed by five 
MS/MS scans within 30 s, with the dynamic exclusion option enabled. 
The spray voltage was 1.9 kV, the temperature of the ion transfer tube 
195°C, and the normalized collision energy was 35% 8.  
   Data-analyzed tandem mass spectra were extracted and the charge 
state deconvoluted and de-isotoped using the Sorcerer 3.4 beta 2 platform 
  9
(Sorcerer software 3.1.4, Sorcerer Web interface 2.2.0 r334, and Trans-, 
Proteomic Pipeline 2.9.5). All MS/MS samples were analyzed using 
SEQUEST (version v.27, rev. 11; ThermoFinnigan, San Jose, CA, USA), 
which was set to search the ipi 3.29 database (IPI ver.3.29, 40131 entries) 
with semitrypsin as the digestion enzyme. The search used a 
fragment-ion mass tolerance of 1.00 Da and a parent-ion mass tolerance 
of 1.5 Da. Iodoacetamide-derivatized cysteine was specified as a fixed 
modification. Methionine oxidation, iodoacetamide derivatizion of 
cysteine, and phosphorylation of serine, threonine, and tyrosine were 
specified as variable modifications.  
 
4. Validation of MS/MS identification and label free quantification 
Scaffold (version Scaffold-2.0; Proteome Software Inc., Portland, OR) 
was used to validate MS/MS-based peptide and protein identifications. 
Peptide identifications were accepted if their probability was >95.0%, as 
specified by the Peptide Prophet algorithm, and they contained at least 
one identified peptide. Protein probabilities were assigned by the Protein 
Prophet algorithm. Proteins containing similar peptides such that they 
could not be differentiated based on MS/MS analysis alone were grouped 
to satisfy the principles of parsimony. The peptide false positive (FPR) 
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rate was calculated using the Scaffold software. For each charge state, 
incorrect assignments were tabulated to calculate the FPRi = [(#Assigned 
Incorrect at 95% probability)/(Total# Incorrect Assigned)]*100, 
with i being the charge state. The assignment is considered correct if it is 
associated with a protein that has a 95% probability, according to the 
Protein Prophet algorithm, and if a minimum of 2 peptides are matched 
with the protein sequence, each with a 95% probability, based on the 
Peptide Prophet algorithm. After identifying the proteins, each dataset 
was used for a subtractive analysis by quantitative value. Quantitative 
value of proteome set was analyzed by label free mass spectrometry 
which count each spectra peaks and normalizes in the Scaffold program9.  
 
5. Bioinformatics analysis 
   Systematic bioinformatics analysis of the GCMN proteome was 
conducted using STRING 8.3 (Search Tool for the Retrieval of 
Interacting Genes/Proteins) 10, PANTHER 7.0 (Protein Analysis Through 
Evolutionary Relationships) classification system 11, the NCBI Clusters 
of Orthologous Groups (COG) database 12, Cytoscape, and ClueGO 13.  
 
6. Western blot analysis 
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   Selected 14-3-3 family proteins were analyzed by Western blot to 
confirm the proteomic results. The proteins were prepared as follows: 
normal skin and GCMN (n = 3 each) were homogenized in lysis buffer 
(Tris–HCL 20 mM, NaCl 150 mM, EDTA 10 mM, NaF 50 mM, NaVO4 
25 mM) and centrifuged at 15,000 × g for 10 min. Equal amounts of 
membrane proteins (30 µg) were separated by 8% SDS-PAGE, followed 
by electrophoretic transfer of the proteins to nitrocellulose membranes 
and blocking overnight in 5% skim milk. The blocked membrane was 
incubated with primary antibodies against 14-3-3 alpha+beta (30 kDa), 
14-3-3 epsilon (29 kDa), 14-3-3 zeta (28 kDa), 14-3-3 sigma (25 kDa), 
14-3-3 tau (31 kDa), or β-tubulin (55 kDa) (Abcam, Cambridge, MA) for 
2 h at room temperature. The membranes were then washed three times 
with PBS and incubated with secondary antibodies [goat anti-mouse IgG 
(Abcam) against 14-3-3 sigma, 14-3-3 theta, and β-tubulin; goat 
anti-rabbit IgG (Abcam) against 14-3-3 alpha+beta, 14-3-3 epsilon, 
14-3-3zeta] for 2 h at room temperature. Images were captured and 
quantified using a Fuji Imager LAS3000 (FujiFilm, Miyagi, Japan) at 
75% of total resolution and 10 to 60s exposure time using the 
Multi-Gauge V2.3 system.  
7. Statistical analysis 
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   Student’s t-test was used to compare the characteristics of the donors 
and samples of normal skin and GCMN. P < 0.05 was considered 
statistically significant.  
III. Results 
1. Characteristics of the study population 
   The average age of the patients contributing the normal skin and 
GCMN samples was not significantly different (10.5 ± 5.31 and 6 ± 1.89, 
respectively, p = 0.09). All GCMN were over 15 cm in diameter. Three of 
the six normal skin samples taken from GCMN donors were analyzed 
using LC-MS or western blotting to minimize environmental bias 
between individuals (Table 1).  
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Table 1. Clinical characteristics of GCMN and normal skin samples  
Sample ID Age Sex Location  Surgery  
Group 1 
Normal 1* 8 Male Groin Skin graft 
Normal 2* 5 Female Face Scar revision 
Normal 3 14 Female Face Scar revision 
GCMN 1* 8 Male Face  
GCMN 2* 5 Female Face  
GCMN 3 8 Male Forehead  
Group 2 
Normal 4* 6 Female Groin Skin graft 
Normal 5 11 Female Face Scar revision 
Normal 6 19 Female Face Scar revision 
GCMN 4* 6 Female Face  
GCMN 5 6 Female Abdomen  
GCMN 6 3 Female Left leg  
* matched skin sample 
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2. Proteomic alterations in GCMN 
   The same amount (20 μg) of soluble proteins was separated using 
SDS-PAGE, which resulted in 15 bands (Figure 1A). The peptide 
spectrum peak of each protein band was acquired (Supplementary Figure 
S1), thereby identifying 438 nonredundant proteins. Among these, 343 
proteins were commonly identified in both groups, 62 were detected only 
in GCMN, and 33 only in normal skin (Figure 1B). Fifty differentially 
expressed proteins (DEPs) were identified, i.e., their expression was 
significantly (p < 0.05) different in GCMN than in normal skin (Figure 
1C). The large majority of these DEPs were upregulated (46 of 50, 92%) 
and very few (4 proteins, 8%) were downregulated (Figure 2, 
Supplementary Table S1). The most highly upregulated protein in GCMN 
was cathepsin D (CTSD), which was expressed at a 6.8-fold higher level 
than in normal skin. In addition, protein disulfide-isomerase A3 precursor 
(PDIA3, 5.4-fold), prohibitin (PHB, 5.3-fold), heat shock protein 70 
(HSPA8, 5.2-fold), D-3-phosphoglycerate dehydrogenase (PHGDH, 
5-fold), and ATP synthase subunit beta (ATP5B, 5-fold) were highly 
(>4-fold) upregulated in GCMN. The four proteins downregulated in 
GCMN were cytokeratin-1 (KRT1, –1.4-fold), filaggrin 2 (FLG2, 
–4.7-fold), hornerin (HRNR, 6.0-fold), and alcohol dehydrogenase 1B 
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(ADH1B, 6.2fold). Note that CTSD overexpression was found in breast 
cancer14, ovarian cancer 15, and human melanoma 16, 17. 
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Figure1. Comparative proteomic analysis of giant congenital melanocytic 
nevi (GCMN) and normal skin using 1D-ESI-LC MS/MS analysis. (A) 
Coomasie-stained gel of normal skin and GCMN proteins (n = 3 each). 
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Band number indicates the matching mass peak result in Supplementary 
Figure S1. (B) Venn diagram of identified proteins in normal and GCMN 
skin. (D) Statistical test of normal skin vs. GCMN proteomes. The 
number of unique peptides of each protein in normal skin and GCMN 
was compared using Student’s t-test, with p < 0.05 considered to be 
significant. 
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Figure 2. Expressional changes of differentially expressed proteins 
(DEPs) in GCMN. The histogram displays the protein symbol and the 
averaged expressional rate of each DEP in GCMN. DEPs comprised 4 
downregulated and 46 upregulated proteins in GCMN vs. normal skin. 
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 3. Systemic properties of altered GCMN proteome 
   The molecular function, biological process association, and COG of 
50 DEPs were analyzed to gain insight into the systemic properties of the 
proteome of GCMN. Among the GCMN proteins with a molecular 
function, alterations in the expression of chaperones (16% of total), 
oxidoreductases (8%), and cytoskeletal elements (7%) were determined 
(Figure 3A). Among the GCMN proteins involved in biological processes, 
signal transduction (15%), cell structure and motility (10%), protein 
metabolism and modification (10%), and cell cycle (10%) proteins were 
markedly altered in their expression. The COG classification showed that 
the DEPs in GCMN were highly enriched in proteins involved in 
posttranslational modification, turnover, chaperones (30%), and the 
cytoskeleton (12%) (Figure 3C), which are consistent with the molecular 
function and biological process classifications.   
   Further network analysis with ClueGO was carried out to identify 
enriched functional groups in GCMN, thus providing detailed 
information on each one. As ontology sources, GO_biological process, 
GO_cellular component, GO_molecular function, KEGG pathway, and 
Reactome_biocarta were selected. The specific functional groups thus 
identified as significantly enriched in GCMN were melanosome 
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(GO_cellular component), neurotrophin signaling pathway (KEGG 
pathway), downregulated of MTA-3 in ER-negative breast tumors 
(Biocarta), cell cycle (KEGG pathway), phospholipase inhibitor activity 
(GO_molecular function), and glycolysis/gluconeogenesis (KEGG 
pathway) (Table 2, Supplementary Figure S2). 
   Since proteins rarely act alone but rather interact as a group, thus 
comprising a functional cluster, a protein–protein interacting network 
was constructed using STRING 8.0. This network consisted of 49 of the 
50 DEPs, with 71 interactions between them. As seen in Figure 4A, 
overlaying the expressional alteration rate of GCMN on this network 
demonstrated the fold-change in GCMN vs. normal skin. In the GCMN 
network, upregulated proteins were tightly linked with each other, 
forming a large cluster. The biological meaning of the cluster was 
determined by overlaying the COG of each protein on the network, 
which revealed that closely neighboring proteins shared COGs (Figure 
4B). Moreover, the GCMN network contained a very highly specific 
protein cluster, identified as the 14-3-3 protein family, whose members 
were expressed at significantly higher levels than in normal skin: 
14-3-3sigma (or SFN, 1.7-fold), 14-3-3 protein beta/alpha (YWHAB, 
2.2-fold), 14-3-3 protein epsilon (YWHAE, 4.2-fold), 14-3-3 protein 
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gamma (YWHAG, 2.1fold), 14-3-3 protein theta (YWHAQ, 3.3fold), and 
14-3-3 protein zeta/delta (YWHAZ, 2.6fold).  
  22
 
Figure 3. Functional categories and the corresponding percentages in the 
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GCMN proteome. Molecular function (A), biological process (B), and 
clusters of orthologous groups (COG) (C) were analyzed using the online 
bioinformatics analysis tools PANTHER (http://www.pantherdb.org/) and 
COGnitor provided by the NCBI database 
(http://www.ncbi.nlm.nih.gov/COG/old/xognitor.html). 
  24
 
Figure 4. The proteome network of congenital melanocytic nevi. (A) 
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Protein–protein interactions between proteins in GCMN, as analyzed by 
String 8.0 and visualized with respect to expression of the corresponding 
protein. (B) The network overlapped with COG functional clustering. 
The proteins 14-3-3sigma (or SFN, 1.7-fold), 14-3-3beta/alpha (YWHAB, 
2.2-fold), 14-3-3 epsilon (YWHAE, 4.2-fold), 14-3-3gamma (YWHAG, 
2.1-fold), 14-3-3theta (YWHAQ, 3.3-fold), and 14-3-3zeta/delta 
(YWHAZ, 2.6-fold) were tightly linked with each other and formed 
specific functional clusters (red circles). A: RNA processing and 
modification, C: Energy production and conversion, D: Cell cycle control, 
cell division, chromosome partitioning, E: Amino acid transport and 
metabolism, G: Carbohydrate transport and metabolism, I: Lipid 
transport and metabolism, J: Translation, ribosomal structure, and 
biogenesis, O: Posttranslational modification, protein turnover, 
chaperones, P: Inorganic ion transport and metabolism, Q: Secondary 
metabolites biosynthesis, transport, and catabolism, R: General function 
prediction only, S: Function unknown, T: Signal transduction 
mechanisms, U: Intracellular trafficking, secretion, and vesicular 
transport, Z: Cytoskeleton. 
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Table 2. Altered major biological pathways in GCMN 
GOID % 
Genes1 
p-Value2 
p-Value/ 
Involved Proteins 
Bonf3 
Cell cycle 
KEGG:04110 5 9.0E-07 4.77E-05 
ANXA1|SFN|YWHAB|YWHAE|YWHAG|
YWHAQ|YWHAZ 
Phospholipase inhibitor activity 
GO:0004859 27.3 3.2E-06 1.68E-04 ANXA1|ANXA2|ANXA5|ARHGDIA|ATP5
B|KRT1 
Melanosome 
GO:004247 12.8 4.1E-16 2.17E-14 
ANXA1|ANXA2|ANXA5|ATP5B|CLIC1|C
TSD|FASN|HRNR|HSP90AA1|HSP90AB1|
HSPA1B|HSPA8|HSPB1|KRT1|PDIA3|RA
C1|SFN|YWHAB|YWHAE|YWHAG|YWH
AZ 
Neurotrophin signaling pathway 
KEGG:04722 6.1 2.4E-09 1.25E-07 
ACTB|ARHGDIA|CAPZA1|CAPZB|CDC42
|HSPB1|MYLK|RAC1|SFN|YWHAB|YWH
AE|YWHAG|YWHAQ|YWHAZ 
Downregulated of MTA-3 in ER-negative breast tumors 
BioCarta:204 28.6 4.9E-08 2.62E-06 
ADH1B|ALDOA|CTSD|ECH1|GAPDH|HSP
B1|PHGDH|RYR3 
Glycolysis/Gluconeogenesis 
KEGG:00010 4.7 7.2E-04 0.038 ADH1B|ALDOA|ECH1|FASN|GAPDH 
1% of associated genes identified in our results/total known genes 
involved in the function or pathway, 2Term p-Value,3Term p-Value with 
Bonferroni correction 
  27
4. Western blot analysis of 14-3-3 family proteins 
   The 14-3-3 family proteins in normal and GCMN skin (n = 3 each) 
were analyzed by Western blotting using samples distinct from the 
proteomic specimens. A comparison with normalized β-actin expression 
showed that the expression of 14-3-3 epsilon was 2.41 ± 0.26 fold (p < 
0.005) higher in GCMN than in normal skin. 
  28
 
Figure 5. Expressional alterations in the 14-3-3 protein family. Western 
blotting shows significantly increased 14-3-3 epsilon expression in the 
GCMN group. *p < 0.05, Student’s t-test (n = 3 in each group) 
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IV. Discussion 
   In the present study, the proteomic composition of GCMN was 
compared with that of normal skin. A major aim of the study was the 
identification of proteins whose expression is enhanced in GCMN to gain 
insight into the mechanism of melanotumorigenesis in these 
malformations. LC-ESI-MS/MS analysis showed that 50 of the 438 
identified proteins were differentially expressed between normal skin and 
GCMN. Among the latter, 92% were upregulated but only 8% were 
downregulated. The use of different bioinformatics tools showed that 
GCMN clearly differed from normal skin in terms of protein expression 
patterns, which suggested that specific biological processes are altered in 
GCMN. As derived from the GO categories, KEGG pathways, and 
Reactome_biocarta, these processes were shown to encompass several 
major biological functions, i.e., the neurotrophin signaling pathway, 
downregulated of MTA-3 in ER-negative breast tumors, the cell cycle, 
phospholipase inhibitor activity, and glycolysis/gluconeogenesis. 
Strikingly, among these, neurotrophin signaling18, 19, MTA-3 
downregulation20, cell cycle deregulation21, and 
glycolysis/gluconeogenesis 22 have been implicated in the development 
and progression of melanoma and other cancers. This suggests that 
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proteomic modifications with tumorigenic potential are present in 
GCMN.  
   Our results also revealed the highly increased expression of cathepsin 
D (CTSD), a molecular maker of malignant cancers, in GCMN. CTSD 
overexpression has also been reported in breast cancer 14, ovarian cancer 
15, and human melanoma 16, 17. In contrast, a comparative proteomic 
analysis of melanocytes and melanoma showed that CTSD is 
downregulated in melanoma 23.  
   The 14-3-3 proteins comprise a highly conserved family whose 
members are found in both plants and mammals. They mediate signal 
transduction by binding to phosphoserine-containing proteins and are 
involved in many biological cellular processes, such as metabolism, 
protein trafficking, signal transduction, apoptosis, and cell cycle 
regulation, through interaction with various phosphoserine-containing 
proteins, such as CDC25 phosphatases, RAF1, and IRS1 proteins. The 
14-3-3 family proteins consist of seven isoforms: beta, gamma, epsilon, 
sigma, zeta, tau, and eta. The alpha and sigma isoforms are the 
phosphoforms of beta and zeta, respectively. All 14-3-3 proteins are 
ubiquitously expressed, with the exception of 14-3-3sigma, which is 
exclusively expressed in epithelial cells 24. Their properties include self 
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assembly into homo- and heterodimers and the ability to enhance the 
activity of many proteins with proliferative and/or survival functions, 
such as Raf kinases, and to inhibit pro-apoptotic proteins, such as Bad, 
Bim, and Bax 25-27. Among the 14-3-3 family members, 14-3-3 sigma 
acts as a tumor suppressor and its expression is upregulated coordinately 
with that of p53 and BRCA128. Since DNA damage induces 14-3-3 sigma 
gene expression, the overexpression of this gene or its respective protein 
is frequently found in cancers such as ovarian carcinomas 29, pancreatic 
cancer 30, papillary carcinoma 31, hepatocellular and carcinoma 31. In 
addition, high frequency of hypermethylation  at the 14-3-3 sigma 
locuswas implicated with breast cancer 32. Given that the loss of 
14-3-3sigma expression sensitizes tumor cells to treatment with 
conventional cytostatic drugs, modulation of 14-3-3 sigma activity might 
be an attractive therapeutic approach 33. In our proteomic results, 
expression of 14-3-3 proteins was significantly higher in GCMN than in 
normal skin, which strongly supports the greater tendency to 
melanotumorigenesis in GCMN. In particular, the enhanced expression 
of 14-3-3 epsilon protein was clearly shown in Western blot analysis 
(Figure 5).  
   Compared to the other isoforms, little is known about the molecular 
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and biological role of 14-3-3 epsilon. However, 14-3-3 epsilon has been 
shown to have an essential role in cell development. Studies in 
Drosophila showed that 14-3-3 epsilon is required for the correct timing 
of mitosis in undisturbed post-blastoderm cell cycles 34. More recently, 
defects in neuronal migration during the development of 14-3-3 epsilon 
knockout mice were reported 35. 
   The phosphorylation-induced binding of 14-3-3 epsilon to the 
pro-apoptotic transcription factor forkhead transcription factor like 1 
(FKHRL1 or FOXO3a) leads to structural changes and inhibits the 
protein’s pro-apoptotic activity 36. In inflammation and carcinogenesis, 
14-3-3 epsilon interacts with key molecules of the mitogen-activated 
protein kinase (MAPK) signal module to selectively modulate tumor 
necrosis factor-alpha (TNF-α)-induced nuclear factor-kappa-beta 
(NF-κB) activity 37. The function and regulatory mechanism of 14-3-3 
epsilon in carcinogenesis is controversial and appears to be 
tumor-specific. Expression of the protein is higher in renal cancerous 
tissues than in normal kidney 38. Moreover, based on their involvement in 
the tumorigenesis of meningioma, 14-3-3 epsilon, zeta, and theta may be 
efficient markers for predicting the degree of malignancy of these tumors 
39. In contrast, mRNA and protein expression of 14-3-3 epsilon in 
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laryngeal squamous cell carcinoma tissues was shown to be significantly 
lower than in normal tissues40. An early role in tumorigenesis is 
suggested by the observation that 14-3-3 epsilon expression is increased 
in intrinsically aged and photoaged human skin 41.  
V. CONCLUSION 
 Through our study, we found out following things (1) Six important 
biological process or pathway, including ‘melanosome, neurotrophin 
signaling pathway, downregulated of MTA-3 in ER-negative breast 
tumors, cell cycle, phospholipase inhibitor activity, and 
glycolysis/gluconeogenesis,  was significantly altered in GCMN skins. 
(2) The intensive alteration of 14-3-3 family proteins possibly act as 
central regulator of GCMN biological pathway remodeling, which has 
important role in development of GCMN and could be associated with 
melanotumorigenesis.  
Because of limitation in available sample, we could not directly check 
the expression level of 14-3-3 proteins in the tissue of malignant 
melanoma, thus, we need further study to validate the functional role of 
14-3-3 proteins in melanotumorigenesis by comparing malignant 
melanoma patient with giant congenital melanocytic nevi. 
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Supplementary Figure S1. Peptide mass peak of 15 bands dissected 
from a 1D gel of normal skin and GCMN.  
  44
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Supplementary Figure S2. The functional network and enriched 
functional group of GCMN was analyzed using ClueGO, a biological 
term enrichment analyzer. The following proteins were significantly 
enriched in GCMN: melanosome (GO_cellular component), 
neurotrophin signaling pathway (KEGG pathway), downregulated of 
MTA-3 in ER-negative breast tumors (Biocarta), cell cycle (KEGG 
pathway), phospholipase inhibitor activity (GO_molecular function), 
and glycolysis/gluconeogenesis (KEGG pathway). 
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Supplementary Table 1. Differentially expressed proteins in GCMN 
Identified proteins  Accession number1 Symbol p-Value 
Fold- 
change 
GeneID2 
 Post-translational modification, protein turnover, chaperones (15) 
 CTSD cathepsin D IPI00011229 CTSD 0.024 6.8 1509 
 HSP90AA1 heat shock protein 90-kDa alpha 
(cytosolic), class A member 1 isoform 1 
IPI00382470  HSP90AA1 0.02 3.4 3320 
 HSP90AB1 heat shock protein HSP 90-beta IPI00414676 HSP90AB1 0.013 3.6 3326 
 HSPA1A;HSPA1B heat shock 70-kDa protein 1 IPI00304925 HSPA1A 0.031 2.4 3303 
 HSPA8 Isoform 1 of heat shock cognate 71-kDa 
protein 
IPI00003865 HSPA8 0.0016 5.2 3312 
 HSPB1 heat shock protein beta-1 IPI00025512 HSPB1 0.0027 3.8 3315 
 PDIA3 protein disulfide-isomerase A3 IPI00025252 PDIA3 0.012 5.4 2923 
 PHB prohibitin IPI00017334  PHB 0.025 5.3 5245 
 PSMB1 proteasome subunit beta type-1 IPI00025019 PSMB1 0.045 3.5 5689 
 SFN Isoform 1 of 14-3-3 protein sigma IPI00013890  SFN 0.027 1.7 2810 
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 YWHAB long isoform of 14-3-3beta/alpha IPI00216318 YWHAB 0.0012 2.2 7529 
 YWHAE 14-3-3 epsilon IPI00000816 YWHAE 0.0051 4.2 7531 
 YWHAG 14-3-3gamma IPI00220642 YWHAG 0.024 2.1 7532 
 YWHAQ 14-3-3theta IPI00018146 YWHAQ 0.00088 3.3 10971 
 YWHAZ 14-3-3zeta/delta IPI00021263 YWHAZ 0.0021 2.6 7534 
 Cytoskeleton (6) 
 A26C1A isoform 1 of ANKRD26-like family C 
member 1A 
IPI00479743 A26C1A 0.0029 4.5 445582 
 ACTB actin, cytoplasmic 1 IPI00021439  ACTB 0.0027 2.3 60 
 CAPZA1 F-actin-capping protein subunit alpha-1 IPI00005969  CAPZA1 0.0044 2.6 829 
 CAPZB cDNA, FLJ93598, highly similar to Homo 
sapiens capping protein (actin filament) muscle Z-line, 
beta  
IPI00641107 CAPZB 0.017 2.9 832 
Isoform 2 of dynein heavy chain 2, axonemal IPI00651691 DNAH2 0.004 2.3 146754 
Isoform 2 of myosin light chain kinase, smooth muscle IPI00221255 MYLK 0.0018 2.6 4638 
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 General function prediction only (5) 
 CDC42 Isoform 2 of cell-division control protein 42 
homolog 
IPI00016786 CDC42 0.017 2.8 998 
 CSPG4 chondroitin sulfate proteoglycan 4 IPI00019157 CSPG4 0.026 2.3 1464 
 HNRNPA2B1 isoform B1 of heterogeneous nuclear 
ribonucleoproteins A2/B1 
IPI00396378  HNRNPA2B1 0.015 4.9 3181 
 PEBP1 phosphatidylethanolamine-binding protein 1 IPI00219446 PEBP1 0.026 2.9 5037 
 RAC1 isoform A of Ras-related C3 botulinum toxin 
substrate 1 
IPI00010271  RAC1 0.0092 3.7 5879 
 Carbohydrate transport and metabolism (4) 
 ALDOA fructose-bisphosphate aldolase A IPI00465439  ALDOA 0.034 4.0 226 
 Uncharacterized protein ENSP00000348237 IPI00453476    0.0012 3.1   
 FLG2 filaggrin-2 IPI00397801 FLG2 0.000021 0.2 388698 
 GAPDH glyceraldehyde 3-phosphate dehydrogenase IPI00219018 GAPDH 0.035 2.2 2597 
 Energy production and conversion (3) 
 ATP5B ATP synthase subunit beta, mitochondrial IPI00303476 ATP5B 0.032 5.0 506 
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 ETFA electron transfer flavoprotein subunit alpha, 
mitochondrial 
IPI00010810  ETFA 0.0028 3.4 2108 
 NDUFS3 NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 3, mitochondrial 
IPI00025796 NDUFS3 0.03 1.7 4722 
 Signal transduction mechanisms (3) 
 ARHGDIA rho GDP-dissociation inhibitor 1 IPI00003815  ARHGDIA 0.047 3.4 396 
 FBLN5 fibulin-5 IPI00294615  FBLN5 0.0028 3.4 10516 
 RYR3 uncharacterized protein RYR3 IPI00217185  RYR3 0.013 2.7 6263 
 Intracellular trafficking, secretion, and vesicular transport (3) 
 ANXA1 annexin A1 IPI00218918 ANXA1 0.03 3.0 301 
 ANXA2 annexin A2 isoform 1 IPI00418169  ANXA2 0.0059 1.8 302 
 ANXA5 annexin A5 IPI00329801  ANXA5 0.025 3.8 308 
 Amino acid transport and metabolism (2) 
 PHGDH D-3-phosphoglycerate dehydrogenase IPI00011200  PHGDH 0.031 5.0 26227 
 TPSB2 TPSB2 IPI00419942  TPSB2 0.043 2.2 64499 
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 Lipid transport and metabolism (2) 
 ECH1 delta(3,5)-delta(2,4)-dienoyl-CoA isomerase, 
mitochondrial 
IPI00011416 ECH1 0.00034 3.1 1891 
 FASN fatty acid synthase IPI00026781 FASN 0.023 3.1 2194 
 Translation, ribosomal structure, and biogenesis (2) 
 EEF1A1 elongation factor 1-alpha 1 IPI00396485  EEF1A1 0.012 2.5 1915 
 RPSA 33-kDa protein IPI00413108 RPSA 0.024 2.9 3921 
 RNA processing and modification (1) 
 HNRNPU short isoform of heterogeneous nuclear 
ribonucleoprotein U 
IPI00479217  HNRNPU 0.0037 2.3 3192 
 Cell cycle control, cell division, chromosome partitioning (1) 
 KRT1 keratin, type II cytoskeletal 1 IPI00220327 KRT1 0.016 0.7 3848 
 Inorganic ion transport and metabolism (1) 
 CLIC1 chloride intracellular channel protein 1 IPI00010896  CLIC1 0.015 3.5 1192 
 Secondary metabolites biosynthesis, transport, and catabolism (1) 
 ADH1B alcohol dehydrogenase 1B IPI00473031  ADH1B 0.025 0.2 125 
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 Function unknown (1) 
 HRNR hornerin IPI00398625 HRNR 0.035 0.2 388697 
Accession Number1: International Protein Index (IPI) accession number, GeneID2: NCBI GeneID 
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ABSTRACT IN KOREAN 
선천성 거대 멜라닌 모반증의 단백질체 분석 
 
<지도교수 탁 관 철 > 
 
연세대학교 대학원 의학과 
 
김 용 규 
 
연구배경:  선천성 거대 멜라닌 모반증은 임상적인 측면에서 
두 가지 중요한 면이 있다. 첫째로는 미용적으로 외모가 
손상되어 환자와 부모에게 정신적 경제적으로 어려운 문제가 
되며 둘째로 흑색종으로의 발병확률이 있다는 것이다. 그러나 
선천성 거대 멜라닌 모반증의 발생원인이나 흑색종이 
발병되는 기전에 대한 단백질체 수준의 연구는 알려져 있지 
않다.  
연구목적: 본 연구의 목적은 선천성 거대 멜라닌 모반증에서 
야기되는 단백질체의 변화양상을 파악 하고, 단백질체의 
변화에 의해 야기 될 수 있는 기능적 변화를 분석하여, 선천성 
거대 모반증의 분자 수준의 이해와 흑색종발병과의 
상관관계를 규명하고자 한다. 
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연구방법:  6명의 선천성 거대 모반증 환아에서 6개의 선천성 
거대 모반 조직과 3개의 정상 피부 조직을 채취하였으며 정상 
환아에서 3개의 피부 조직을 채취하였다. 각각 3개씩의 정상 
피부조직과 선천성 멜라닌 모반증 피부조직의 단백질체 
분석을 액상 크로마토그래픽 텐덤 질량분석법 (LC-MS/MS 
분석)으로 분석 비교하였으며, 의미있는 단백질의 상대적 발현 
변화를 각각 3개씩의 정상과 선천성 멜라닌 모반증 조직에서 
Western blot 분석을 통해 확인하였다. 정상과 질병군에 발현 
변화가 유의하게 변화되는 단백질들을 선별하여, 이들 단백질 
군의 시스템적 분석을 생체정보학 분석 프로그램들을 
이용하여 분석하였다.  
연구결과: 정상과 질병군의 피부 단백질체 분석에서 50개 
단백질이 발현량에 유의한 차이를 보였으며 (p<0.05). 
질병군에서 4개의 단백질 발현량이 감소하였으며, 46개 
단백질의 발현량이 증가하였다. 발현 변화단백질들은 분자적 
기능 분석 상에서 샤페론 단백질(chaperone proteins)이 
15.7% 로 가장 높은 비율을 차지하였으며, 생물학적 기능분석 
상에서는 신호 전달 단백질이 15.3%로 가장 높은 비율로 
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분석되었다. 특히 질병군의 단백질 변화는 뉴트로핀 신호조절, 
멜라노좀, 에스트로겐 수용체 음성(ER-negative) 유방암 관련  
단백질군등과 기능적 연관을 가지고 있었다. 또한, 질병군에서 
14-3-3 단백질군의 발현이 질병군에서 크게 증가하였으며.  
Western blot 분석 결과, 14-3-3 엡실론 발현 증가가 확인 
되었다.  
결론: 선천성 멜라닌 모반증의 단백질체 분석을 통해 14-3-3 
단백질들의 증가를 확인하였으며 이것이 선천성 거대 모반증
의 생물학적 경로 리모델링의 중요한 단백질일 가능성이 있음
을 발견하였다. 특히 14-3-3 엡실론의 증가는 발생학적으로 
선천성 멜라닌 모반증의 발현과 밀접한 관련이 있으며 흑색종
의 발병과도 연관성이 있을 것으로 추정되며 선천성 거대 모
반증 환자에서 흑생종으로 발현된 환자와의 비교에 대한 추가 
연구가 필요하다  
 
 
----------------------------------------------
핵심 되는 말: 선천성 멜라닌 모반증, 흑색종, 14-3-3 엡실론 
